Elena V. Chub

Elena V. Chub

Auto-generated profile, based on publicly available information

Elena V. Chub

State Scientific Center of Virology and Biotechnology “Vector

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
Vladimir A. TernovoiVladimir A. Ternovoi
Vladimir A. Ternovoi
RLROMAN LUTKOVSKII
ROMAN LUTKOVSKII
Eugenia PonomarevaEugenia Ponomareva
Eugenia Ponomareva
Anastasia GladyshevaAnastasia Gladysheva
Anastasia Gladysheva
ECE. V. Chub
E. V. Chub
RMR. A. Maksyutov
R. A. Maksyutov
In this work we tested two reagent kits developed by us for detecting SARS-CoV-2 RNA using a fragment of the ORF1ab gene in digital PCR and real-time PCR formats. Data were obtained on the detection of SARS-CoV-2 virus RNA in nasopharyngeal swabs of patients with COVID-19 and asymptomatic carriers. The developed reagent kits provided 100% sensitivity and a detection limit of 103 GE / ml for qPCR, and at least 200 copies / ml of viral RNA when performing digital PCR. These methods were tested using a panel of 1,328 samples collected from patients with suspected COVID-19 at the beginning of 2020 in the Russian Federation. It has been shown that dPCR is more sensitive and can be used to analyze samples with low viral load, including those from patients without clinical symptoms. dPCR significantly improves the accuracy of laboratory research and significantly reduces the number of false negative results in the diagnosis of SARS-CoV-2. Determination of the concentration of SARS-CoV-2 RNA in patients with different clinical course of the disease showed that the concentration of viral RNA can sharply decrease in the first days of the disease. A low concentration of viral RNA in samples from patients is also characteristic of asymptomatic disease. Digital PCR provides a higher detection rate for asymptomatic cases, which is approximately 75% of those infected, as opposed to 45% for real-time PCR. The results obtained on the use of the digital PCR method for detecting SARS-CoV-2 RNA showed that this method is especially suitable for detecting RNA in case of its low concentration in contacts, as well as for monitoring changes in viral load in convalescent patients.

19 November 2022 in Problems of Virology
Verified
Journal Article
Open access
PDF file
MKMikhail Kartashov
Mikhail Kartashov
KSKirill A. Svirin
Kirill A. Svirin
EKEkaterina I. Krivosheina
Ekaterina I. Krivosheina
ECElena V. Chub
Elena V. Chub
Vladimir A. TernovoiVladimir A. Ternovoi
Vladimir A. Ternovoi
GKGalina Kochneva
Galina Kochneva
Introduction. Parenteral viral hepatitis (B, C, D) and HIV share modes of transmission and risk groups, in which the probability of infection with two or more of these viruses simultaneously is increased. Mutual worsening of the course of viral infections is important issue that occurs when HIV positive patients are coinfected with parenteral viral hepatitis. The aim of the study was to determine the prevalence of HCV, HBV and HDV in HIV positive patients in the Novosibirsk region and to give molecular genetic characteristics of their isolates. Materials and methods. Total 185 blood samples were tested for the presence of total antibodies to HCV, HCV RNA, HBV DNA and HDV RNA. The identified isolates were genotyped by amplification of the NS5B gene fragment for HCV, the polymerase gene for HBV and whole genome for HDV. Results. The total antibodies to HCV were detected in 51.9% (95% CI: 44.758.9), HCV RNA was detected in 32.9% (95% CI: 26.639.5) of 185 studied samples. The distribution of HCV RNA positive cases completely repeated the distribution of HCV serological markers in different sex and age groups. The number of HCV infected among HIV positive patients increases with age. HCV subgenotypes distribution was as follows: 1b (52.5%), 3а (34.5%), 1а (11.5%), 2а (1.5%). 84.3% of detected HCV 1b isolates had C316N mutation associated with resistance to sofosbuvir and dasabuvir. The prevalence of HBV DNA in the studied samples was 15.2% (95% CI: 10.721.0). M204I mutation associated with resistance to lamivudine and telbivudine was identified in one HBV isolate. Two HDV isolates that belonged to genotype 1 were detected in HIV/HBV coinfected patients. Conclusion. The data obtained confirm the higher prevalence of infection with parenteral viral hepatitis among people living with HIV in the Novosibirsk region compared to the general population of that region. The genetic diversity of these viruses among HIV infected individuals is similar to that observed in the general population.

6 July 2023 in Problems of Virology
Verified
Journal Article
Open access
PDF file
MKMikhail Kartashov
Mikhail Kartashov
KSKirill A. Svirin
Kirill A. Svirin
ABAjbek A. Bekbolotov
Ajbek A. Bekbolotov
KMKunduz Momushova
Kunduz Momushova
BIBaarinisa Iskanova
Baarinisa Iskanova
NGNatalya Gashnikova
Natalya Gashnikova
Introduction. The countries of Central Asia, including Kyrgyzstan, are characterized by high prevalence and morbidity of HCV infection. Identification of HCV genotype and mutations associated with resistance to direct-acting antiviral (DAA) plays an important role either in conducting molecular epidemiological studies or choosing the treatment tactics. The aim of the work was to research of the genotype diversity of HCV variants circulating in Kyrgyzstan and the identification among them the mutations associated with the development of resistance to DAA. Materials and methods. 38 serum samples from HCV-infected residents of Kyrgyzstan were analyzed in this study. The nucleotide sequences of viral gene fragments (NS3, NS5A, NS5B) were determined by Sangers sequencing and deposited in the international GenBank database under the numbers ON841497ON841534 (NS5B), ON841535ON841566 (NS5A), and ON841567ON841584 (NS3). Results. The HCV subtypes 1b (52.6%; 95% CI 37.367.5%), 3a (44.8%; 95% CI 30.260.2%) and 1a (2.6%; 95% CI 0.513.4%) are circulating in Kyrgyzstan. 37% (95% CI 1959%) of subtype 1b isolates had C316N mutation in the NS5A gene; 46% (95% CI 2370%) had F37L mutation in the NS5A gene; 45% (95% CI 2272%) had Y56F mutation in the NS3 gene. Among subtype 3a isolates, resistance-associated mutations in NS5B fragment were not found. 22% (95% CI 945%) of subtype 3a sequences had a Y93H mutation in the NS5A gene. A combination of Y56F + Q168 + I170 mutations was identified among all sequences of NS3 gene. DAA resistance mutations were not found in NS3, NS5A, NS5B genes of subtype 1a sequence. Conclusion. A rather high prevalence of mutations associated with resistance or significant decrease in sensitivity to DAA among HCV sequences from Kyrgyzstan was shown. Updating of data on HCV genetic diversity is necessary for timely planning of measures to combat epidemic.

15 September 2019 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
Vladimir A. TernovoiVladimir A. Ternovoi
Vladimir A. Ternovoi
YKYulia Kononova
Yulia Kononova
АЗАнна Владимировна Зайковская
Анна Владимировна Зайковская
ECE. V. Chub
E. V. Chub
AVA. S. Volynkina
A. S. Volynkina
Valeriy B LoktevValeriy B Loktev
Valeriy B Loktev
This study presents the results of laboratory trials of the reagent kit for the rapid detection of RNA of the Crimean-Congo hemorrhagic fever virus (CCHFV) using loop-mediated isothermal amplification with reverse transcription (RT-LAMP). The developed RT-LAMP reagent kit was used to detect the CCHFV and showed a sensitivity of 103 GE/ml of viral RNA, which is sufficient for detection of the CCHFV in the early stage of human infections. The kit showed high specificity and no cross-reactivity with viral panel from the State collection of viruses of the FBRI SRC VB «Vector» (arboviruses and hemorrhagic fever viruses). Laboratory trials of the RT-LAMP kit are showed a high analytical and diagnostic sensitivity and specificity for RNA detection of the CCHFV and high speed of the analysis (60-70 min with sample preparation) compared to real-time PCR. Approbation of the kit field version has showed the possibility of setting the RT-LAMP reaction and viral RNA detection without the using of analytical equipments.

6 January 2024 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
MKMikhail Kartashov
Mikhail Kartashov
KSK. A. Svirin
K. A. Svirin
EKE. I. Krivosheina
E. I. Krivosheina
ECE. V. Chub
E. V. Chub
Vladimir A. TernovoiVladimir A. Ternovoi
Vladimir A. Ternovoi
GKGalina Kochneva
Galina Kochneva
Relevance. Hepatitis B often causes liver cirrhosis and hepatocellular carcinoma, especially among patients with HIV. Vaccination is the main prophylaxis of HBV for preventing infection and developing chronic disease. Studying the duration of postvaccination immunity and the expediency of revaccination in different age and risk groups is important for improving the strategy of immunoprophylaxis of B hepatitis.Aims. Study was to determine the level of post-vaccination immunity to HBV and specific antibodies (anti-HBc and anti-HBs) among HIV-positive patients and the healthy population of Novosibirsk and Tomsk.Materials and methods. 536 blood samples were taken from HIV-positive patients and 337 blood samples from healthy people (pregnant women and persons undergoing a routine medical examination). The presence of HBsAg, anti-HBs IgG, and anti-HBcIgG were determined in the samples.Results. The proportion of post-vaccination immunity decreased in older age groups with an increase in the proportion of post-exposure immunity. The proportion of HIV-positive patients who had contact with HBV was higher than among healthy people. Around 70% of people in each group had a low level of protective antibodies anti-HBs (lower than 100 IU). A high level of anti-HBs (higher than 400 IU) was determined in 10% of examined people. The proportion of low levels of anti-HBs increased with age, while average and high levels of post-vaccination immunity were less common with increasing age.Conclusion. A low proportion of HIV-positive people, who have been effectively vaccinated against hepatitis B, was noticed. Annual blood tests for the presence of HBsAg, anti-HBs, and anti-HBc, in combination with determining DNA HBV, can be recommended for HIV-positive patients who have a risk of developing an occult form of hepatitis B.

1 March 2026 in Molecular Genetics, Microbiology and Virology
Verified
Journal Article
Closed access
PDF file
EKE. I. Krivosheina
E. I. Krivosheina
ECE. V. Chub
E. V. Chub
MKMikhail Kartashov
Mikhail Kartashov
Yellow fever virus (YFV), transmitted by Aedes aegypti mosquitoes, poses a serious threat to public health in the countries of tropical and subtropical reg